ArticleCancer science2003
Clinical implications of expression of ETS-1 in relation to angiogenesis in ovarian cancers.
Article in Cancer science, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Evaluation of the role of kefir in management of non-alcoholic steatohepatitis rat model via modulation of NASH linked mRNA-miRNA panel.Scientific reports · 2023Article
- Phosphorylation-mediated interaction between human E26 transcription factor 1 and specific protein 1 is required for tumor cell migration.Acta biochimica et biophysica Sinica · 2022Article
- Modulation of hepatic stellate cells by MutaflorJournal of translational medicine · 2022Article
- Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma.Cell death & disease · 2022Article
- Transcription Factors in Cancer Development and Therapy.Cancers · 2020Review
- Long non-coding RNA PAXIP1-AS1 facilitates cell invasion and angiogenesis of glioma by recruiting transcription factor ETS1 to upregulate KIF14 expression.Journal of experimental & clinical cancer research : CR · 2019Article
- Upregulation of Ets1 expression by NFATc2 and NFKB1/RELA promotes breast cancer cell invasiveness.Oncogenesis · 2018Article
- Upregulation of Endothelin-1/Endothelin A Receptor Expression Correlates with Heparanase Expression in Ovarian Carcinoma.Iranian journal of medical sciences · 2018Article
- Histochemical and Immunohistochemical Study of α-SMA, Collagen, and PCNA in Epithelial Ovarian NeoplasmAsian Pacific journal of cancer prevention : APJCP · 2017Article
- A network model for angiogenesis in ovarian cancer.BMC bioinformatics · 2015Article
- COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer.Oncogene · 2014Article
- Ets-1 global gene expression profile reveals associations with metabolism and oxidative stress in ovarian and breast cancers.Cancer & metabolism · 2013Article
- Expression of Ets-1, Ang-2 and maspin in ovarian cancer and their role in tumor angiogenesis.Journal of experimental & clinical cancer research : CR · 2011Article
- The role of ets factors in tumor angiogenesis.Journal of oncology · 2010Article
- ETS-1 and ETS-2 are upregulated in a transgenic mouse model of pigmented ocular neoplasm.Molecular vision · 2008Article
- Expression of Ets-1 in human clear cell renal cell carcinomas: implications for angiogenesis.Cancer science · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ETS-1 has been identified as a transcription factor involved in tumor angiogenesis, which is essential for the growth, invasion, and metastasis of solid tumors. This result prompted us to study whether ETS-1 works as an angiogenic mediator in ovarian cancers. Immunohistochemical staining revealed that ETS-1 was expressed in vascular endothelial cells and in cancer cells of ovarian cancers. There was a significant correlation between microvessel counts and both ETS-1 histoscores and ets-1 mRNA levels in ovarian cancers. Both ETS-1 histoscores and ets-1 mRNA levels increased with the progression of ovarian cancers. Furthermore, the 24-month survival rate of 30 patients with high ets-1 (high ETS-1 histoscores and high ets-1 mRNA levels) was 30%, while that of 30 other patients with low ets-1 (low ETS-1 histoscores and ets-1 mRNA levels) was 70%. There was a significant difference between the 24-month survival rates of the 30 patients with high ets-1 and the 30 with low ets-1. This indicates that ETS-1 might act as an angiogenic mediator in, and be a prognostic factor for, ovarian cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.